Richmond Pharmacology’s first year audited accounts showed a healthy profit and increased study placements over original projections.
Exceeding Expectations
Commenting on the financial results for 2002, Jörg Täubel Managing Director, stated:“It has been an excellent year for Richmond Pharmacology. The level of bookings for trials has continued to grow throughout our first year, and we have doubled our capacity for volunteers accordingly. We are delighted to announce that at the end of our first year of trading we exceeded all expectations in terms of studies completed and by showing profitability.“With good order books and detailed plans to accommodate more trials through the coming year, we are well positioned for another year of profitable growth for Richmond Pharmacology.”
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.